User login
Following the confirmation by the U.S. Senate of Robert Califf, MD, as Commissioner of the Food and Drug Administration (FDA), NORD President and CEO Peter L. Saltonstall issued the following statement:
“On behalf of the rare disease community, I want to congratulate Dr. Califf on being confirmed as Commissioner of the FDA. Dr. Califf has spoken to NORD in the past and is familiar with the special issues facing our community. We look forward to working with him closely in the future.”
Prior to joining FDA in February 2015, Dr. Califf was Professor of Medicine and Vice Chancellor for clinical and translational research at Duke University. He is an internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research.
Following the confirmation by the U.S. Senate of Robert Califf, MD, as Commissioner of the Food and Drug Administration (FDA), NORD President and CEO Peter L. Saltonstall issued the following statement:
“On behalf of the rare disease community, I want to congratulate Dr. Califf on being confirmed as Commissioner of the FDA. Dr. Califf has spoken to NORD in the past and is familiar with the special issues facing our community. We look forward to working with him closely in the future.”
Prior to joining FDA in February 2015, Dr. Califf was Professor of Medicine and Vice Chancellor for clinical and translational research at Duke University. He is an internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research.
Following the confirmation by the U.S. Senate of Robert Califf, MD, as Commissioner of the Food and Drug Administration (FDA), NORD President and CEO Peter L. Saltonstall issued the following statement:
“On behalf of the rare disease community, I want to congratulate Dr. Califf on being confirmed as Commissioner of the FDA. Dr. Califf has spoken to NORD in the past and is familiar with the special issues facing our community. We look forward to working with him closely in the future.”
Prior to joining FDA in February 2015, Dr. Califf was Professor of Medicine and Vice Chancellor for clinical and translational research at Duke University. He is an internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research.
